Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Significant Growth in Short Interest

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 2,004 shares, a growth of 235.7% from the June 30th total of 597 shares. Based on an average trading volume of 10,079 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Santen Pharmaceutical Price Performance

Shares of SNPHY opened at $11.65 on Monday. Santen Pharmaceutical has a 1-year low of $9.22 and a 1-year high of $13.93. The stock has a market cap of $3.76 billion and a PE ratio of 0.10. The firm has a fifty day moving average price of $12.48 and a 200 day moving average price of $11.53.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.